Ipilimumab, a new molecular targetted therapy of malignant neoplastic disease

Takahiro Mori

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Ipilimumab is a fully human monoclonal antibody that binds to CTLA-4 (cytotoxic T lymphocyte-associated antigen 4). It is intended to be used as a drug to activate the immune system by binding to CTLA-4, which suppresses T-cells in natural immune responses. Recently, a phase III, multi-center, randomized, double-blind, clinical study showed an improvement in over-all/progression-free survival in patients with advanced melanomas. Ipilimumab is undergoing clinical trials for the treatment of melanoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and metastatic hormone-refractory prostate cancer, as well as other neoplastic diseases.

Original languageEnglish
Pages (from-to)31-35
Number of pages5
JournalJapanese Journal of Cancer and Chemotherapy
Issue number1
Publication statusPublished - 2011 Jan


  • CTLA-4
  • Clinical trial
  • Fully human monoclonal antibody
  • Melanoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Ipilimumab, a new molecular targetted therapy of malignant neoplastic disease'. Together they form a unique fingerprint.

Cite this